Metabolic Solutions Development Co. LLC
Treating metabolic disease by way of the mitochondria
This article was originally published in Start Up
Metabolic Solutions Development thinks it knows why diabetes drugs directed against PPAR-γ ran into safety problems. The start-up is leveraging insights about what not to do, as it works to create an insulin sensitizer that lowers blood glucose levels without increasing white fat and without causing dangerous side effects.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.